Printer Friendly

DANNINGER MEDICAL TECHNOLOGY, INC. ANNOUNCES 1992 RESULTS

 COLUMBUS, Ohio, March 19 /PRNewswire/ -- Danninger Medical Technology, Inc. (NASDAQ: DANN) today announced a net loss of $47,803, or $(0.01) per share, for the twelve months ended Dec. 31, 1992, compared to net income of $400,858, or $0.09 per share, a year ago. Total revenue declined to $7,394,254 in 1992 from $8,443,652 in 1991. Strategic changes were made in the distribution channels for all of the company's products during 1992 which resulted in a significant, but temporary impact on total revenue compared to the previous year. The company's commitment to research and development was maintained and represented approximately 13 percent of total revenue for the full year 1992.
 Total revenue for the three months ended Dec. 31, 1992 declined to $1,819,890 from $2,425,276 for the same period in 1991. The net loss was $65,749, or $(0.01) per share, for the fourth quarter of 1992 versus net income of $268,095, or $0.06 per share a year ago.
 A number of positive factors occurred during the fourth quarter of 1992 which are expected to favorably impact 1993 results. A new Continuous Passive Motion (CPM) product, the Danniflex(TM) Toe/Wrist CPM, performing well in the market and is generating solid orders from dealers. Cross Medical Products, Inc., a wholly-owned subsidiary, completed the clinical study required for FDA approval of Cross' pedicle screw fixation system. Following FDA marketing clearance for general distribution of the P/W/B Lumbosacral System earlier in the year, product training was significantly expanded for both independent agents and surgeons.
 Danninger Medical Technology, Inc. designs, manufactures, and markets medical devices that assist patients in their recovery following surgery or trauma. Danninger is a leader in Continuous Passive Motion devices for the knee, hip, and hand. Cross Medical Products, Inc. specializes in developing and marketing orthopedic surgical instrumentation and spinal implants.
 Danninger Medical Technology, Inc.
 Financial Highlights
 Three Months Ended
 December 31
 1992 1991
 Total Revenues $1,819,890 $2,425,276
 Net Income (65,749) 268,095
 Net Income Per Share (.01) .06
 Twelve Months Ended
 December 31
 1992 1991
 Total Revenues $7,394,254 $8,443,652
 Net Income (47,803) 400,858
 Net Income Per Share (.01) .09
 Weighted Average Shares
 Outstanding Including
 Common Stock Equivalents 4,394,122 4,469,903
 As of December 31
 1992 1991
 Total Assets $7,966,400 $6,955,027
 Working Capital 4,065,968 3,509,265
 Shareholders' Equity 3,727,160 3,745,193
 -0- 3/19/93
 /CONTACT: John Jenkins, chief financial officer of Danninger Medical Technology, Inc., 614-276-8267/
 (DANN)


CO: Danninger Medical Technology, Inc. ST: Ohio IN: MTC SU: ERN

BM -- CL002 -- 7835 03/19/93 10:42 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 19, 1993
Words:458
Previous Article:DAVINCI INTRODUCES COMPUSERVE AS ADDITIONAL SUPPORT OPTION CompuServe dial-in access for DaVinci eMAIL users
Next Article:BALL CORPORATION COMPLETES ACQUISITION OF HEEKIN CAN, INC.
Topics:


Related Articles
DANNINGER MEDICAL TECHNOLOGY, INC. ANNOUNCES HIGHER SECOND QUARTER AND FIRST HALF RESULTS
DANNINGER MEDICAL TECHNOLOGY, INC. ANNOUNCES IMPROVED SECOND QUARTER RESULTS
DANNINGER MEDICAL TECHNOLOGY, INC. ANNOUNCES HIGHER THIRD QUARTER REVENUES AND IMPROVED RESULTS
DANNINGER MEDICAL TECHNOLOGY, INC. ANNOUNCES RECORD SALES FOR 1993; NET LOSS DUE TO PROVISIONS FOR CERTAIN INVENTORY AND ACCOUNTS RECEIVABLE
DANNINGER MEDICAL TECHNOLOGY ANNOUNCES FIRST QUARTER RESULTS
DANNINGER MEDICAL TECHNOLOGY, INC. REPORTS IMPROVED SALES, NET INCOME FOR FOURTH QUARTER, FULL YEAR 1994
DANNINGER MEDICAL TECHNOLOGY, INC. REPORTS RECORD FIRST QUARTER SALES
DANNINGER MEDICAL TECHNOLOGY, INC. REPORTS HIGHER SALES, NET LOSS DUE TO SYNERGY SPINAL IMPLANT SYSTEM INTRODUCTION
DANNINGER MEDICAL TECHNOLOGY, INC. REPORTS RECORD FIRST QUARTER SALES
Danninger Medical Announces Final Results For the Fourth Quarter and for the Year

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters